| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 666 | 2021 |
| Lysophosphatidic acid is a potential mediator of cholestatic pruritus AE Kremer, JJWW Martens, W Kulik, F Ruëff, EMM Kuiper, ... Gastroenterology 139 (3), 1008-1018. e1, 2010 | 438 | 2010 |
| Vascular occlusion by neutrophil extracellular traps in COVID-19 M Leppkes, J Knopf, E Naschberger, A Lindemann, J Singh, I Herrmann, ... EBioMedicine 58, 2020 | 432 | 2020 |
| The biliary HCO3− umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies U Beuers, S Hohenester, LJM de Buy Wenniger, AE Kremer, PLM Jansen, ... Hepatology 52 (4), 1489-1496, 2010 | 391 | 2010 |
| Uremic pruritus T Mettang, AE Kremer Kidney international 87 (4), 685-691, 2015 | 312 | 2015 |
| Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions AE Kremer, R van Dijk, P Leckie, FG Schaap, EMM Kuiper, T Mettang, ... Hepatology 56 (4), 1391-1400, 2012 | 282 | 2012 |
| Pruritus in cholestasis: facts and fiction U Beuers, AE Kremer, R Bolier, RPJO Elferink Hepatology 60 (1), 399-407, 2014 | 238 | 2014 |
| SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases D Simon, K Tascilar, F Fagni, G Krönke, A Kleyer, C Meder, R Atreya, ... Annals of the rheumatic diseases 80 (10), 1312-1316, 2021 | 195 | 2021 |
| Fibroblast growth factor 21 is induced by endoplasmic reticulum stress FG Schaap, AE Kremer, WH Lamers, PLM Jansen, IC Gaemers Biochimie 95 (4), 692-699, 2013 | 194 | 2013 |
| Pathogenesis and treatment of pruritus in cholestasis AE Kremer, U Beuers, RPJ Oude-Elferink, T Pusl Drugs 68, 2163-2182, 2008 | 169 | 2008 |
| Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised … D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ... The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017 | 163 | 2017 |
| Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR S Holdenrieder, P Stieber, LYS Chan, S Geiger, A Kremer, D Nagel, ... Clinical chemistry 51 (8), 1544-1546, 2005 | 155 | 2005 |
| Clinical relevance of circulating nucleosomes in cancer S Holdenrieder, D Nagel, A Schalhorn, V Heinemann, R Wilkowski, ... Annals of the New York Academy of Sciences 1137 (1), 180-189, 2008 | 154 | 2008 |
| Pathophysiology and current management of pruritus in liver disease AE Kremer, RPJO Elferink, U Beuers Clinics and research in hepatology and gastroenterology 35 (2), 89-97, 2011 | 153 | 2011 |
| The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis C Günther, GW He, AE Kremer, JM Murphy, EJ Petrie, K Amann, ... The Journal of clinical investigation 126 (11), 4346-4360, 2016 | 151 | 2016 |
| PU. 1 controls fibroblast polarization and tissue fibrosis T Wohlfahrt, S Rauber, S Uebe, M Luber, A Soare, A Ekici, S Weber, ... Nature 566 (7744), 344-349, 2019 | 145 | 2019 |
| Increased frequencies of IL‐31‐producing T cells are found in chronic atopic dermatitis skin K Szegedi, AE Kremer, S Kezic, MBM Teunissen, JD Bos, RM Luiten, ... Experimental dermatology 21 (6), 431-436, 2012 | 145 | 2012 |
| Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum S Abu‐Hayyeh, C Ovadia, TM Lieu, DD Jensen, J Chambers, PH Dixon, ... Hepatology 63 (4), 1287-1298, 2016 | 144 | 2016 |
| Receptors, cells and circuits involved in pruritus of systemic disorders AE Kremer, J Feramisco, PW Reeh, U Beuers, RPJO Elferink Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1842 (7), 869-892, 2014 | 112 | 2014 |
| Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion D Simon, K Tascilar, G Krönke, A Kleyer, MM Zaiss, F Heppt, C Meder, ... Nature communications 11 (1), 3774, 2020 | 104 | 2020 |
